Development of technology and capabilities critical for clinical translation of first of its kind brain tumour therapy

开发对首个脑肿瘤疗法的临床转化至关重要的技术和能力

• 批准号: 10048434
• 金额: $ 76.86万
• 依托单位: QV BIOELECTRONICS LTD
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10048434
• 关键词: Development; technology; capabilities; critical; clinical

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and the 5-year survival rate is ~3.4%.Electric Field therapy (EFT) is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the only available electrotherapy device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness.QV Bioelectronics (QVB) is developing GRACE, a first of its kind implanted EFT device. GRACE delivers EFT in a focal and continuous manner that will potentially double glioblastoma patient life expectancy, leading to up to 10-times higher 5-year survival rates whilst overcoming quality-of-life issues associated with the existing EFT treatment. QVB have demonstrated initial safety during preclinical development, with pre-clinical efficacy testing taking place in parallel to this project. As part of this project, QVB aims to carry out additional development steps to ensure GRACE will be ready for 1st in human trials in UK patients by the end of 2024\.QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, with our research and innovation hub creating a significant number of jobs in the UK, creating a combined global market opportunity worth over £3.9Bn/year. This will cement the UK's position as global leaders in the growing field of bioelectronics.

胶质母细胞瘤是最常见和最具侵袭性的原发性成人脑癌。全球发病率为3-5/100，000人，并呈上升趋势，英国每年约有3000例诊断。目前尚无治愈方法，5年生存率约为3.4%。电场疗法（EFT）是一种在肿瘤切除术后应用的新型癌症治疗方法，可直接干扰细胞分裂，减缓肿瘤复发，延长生命。然而，由于患者生活质量差和成本效益低，NICE不建议在NHS上使用唯一可用的胶质母细胞瘤电疗设备。QV Bioelectronics（QVB）正在开发GRACE，这是第一种植入式EFT设备。GRACE以局部和连续的方式提供EFT，可能使胶质母细胞瘤患者的预期寿命增加一倍，使5年生存率提高10倍，同时克服与现有EFT治疗相关的生活质量问题。QVB已在临床前开发期间证明了初步安全性，临床前有效性测试与本项目同时进行。作为该项目的一部分，QVB的目标是进行额外的开发步骤，以确保GRACE将在2024年底前在英国患者中首次进行人体试验。QVB的技术未来将扩展到其他类型的脑肿瘤，我们的研究和创新中心将在英国创造大量就业机会，创造一个价值超过39亿英镑/年的全球市场机会。这将巩固英国在不断发展的生物电子领域的全球领导者地位。